AUM-Biosciences

AUM BIOSCIENCES participated in Panel Discussion at Digital Pharma Summit, Singapore, 18th – 21 September 2018

Singapore, 18 – 21 September 2018

Mr. Vishal Doshi, AUM Biosciences’ Founder and Chief Executive Officer participated in an Industry Panel Discussion at the Digital Pharma Summit, held on 19th September 2018 at OneFarrer Hotel & Spa, from 5.30 pm – 6.00 pm.

The Panel Discussion, on the topic, Digital Transformation in the Asian context, covered the following themes:

Examining the current impact of digitalisation in the Asian Pharma sector
What touch points will have most influence
How is Pharma – HCP – Patient engagement going to change
Pharma and Consumer interface evolution
What is needed to give Pharma a digital boost

CEO and Founder of AUM Biosciences.
A Pharmacist by training
An experienced senior manager with extensive experience in clinical research related experience across the Pharmaceutical/CRO Industry.
Played a key role in implementing and championing digital health and analytics initiatives. His current company, AUM Biosciences, is also built on an integral pillar of implementing digitalization in drug development.
Committed to “smart data” driven approaches, which prioritises efficient use of aggregated data, by learning and analysis, early in the process to reduce the cost and the speed of the drug development.
Experience spanning the EU, Asia, and US, where he was worked with the TOP 10 CROs in the industry (e.g., Quintiles). Headed the Asian business development for one of Japan’s largest CRO.
Widely recognised as a Key Opinion Leader with the Korean Health Industry Development Institute, where he contributes in supporting Korea’s globalisation plans of commercialisation of various therapies.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com